✦ LIBER ✦

Prostate Cancer and Immunoproteome: Awakening and Reprogramming the Guardian Angels

✍ Scribed by Ammad Ahmad Farooqi; Sundas Fayyaz; Muhammad Zahid Qureshi; Sadia Rashid

Book ID: 113013695
Publisher: Springer
Year: 2012
Tongue: English
Weight: 328 KB
Volume: 60
Category: Article
ISSN: 0004-069X
DOI: 10.1007/s00005-012-0169-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

MP24-10 DRUG EFFICACY REPROGRAMMING BY R

MP24-10 DRUG EFFICACY REPROGRAMMING BY RIBAVIRIN AGAINST THE CANCER STEMNESS IN DOCETAXEL-RESISTANT PROSTATE CANCER

✍ Kosaka, Takeo; Nagamatsu, Go; Mikami, Shuji; Miyajima, Akira; Yasumizu, Yota; Mi 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 193 KB

P03-10 Epigenetic reprogramming of IGFBP

P03-10 Epigenetic reprogramming of IGFBP-2 in prostate cancer mediates hyperglycaemia-induced chemoresistance and the effect of metformin

✍ Biernacka, K.; Perks, C.; Gillatt, D.; Persad, R.; Uzoh, C.; Holly, J. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Gene therapy for prostate cancer at the

Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions

✍ Allan J. Pantuck; Amnon Zisman; Arie S. Belldegrun 📂 Article 📅 2000 🏛 Springer-Verlag 🌐 English ⚖ 136 KB

Commentary on Murine cell lines derived

Commentary on Murine cell lines derived from PTEN null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development: Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H, Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles, CA

✍ Haojie Huang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Drug interactions between the proteasome

Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF), and TNF-related apoptosis-inducing ligand (TRAIL) in prostate cancer: An J, Sun Y-P, Adams J, Fisher M, Belldegrun A, Rettig MB, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA [J An, Y-PS, MF, MBR]; Millennium Pharmaceuticals, Inc., Cambridge, MA [J Adams]; and University of California at Los Angeles School of Medicine, Los Angeles, CA [AB, MBR]. Clinical Cancer Research 2003;9:4537–4545

✍ Gurkamal Chatta 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 18 KB

Progression of prostate cancer by synerg

Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor: Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, Witte ON, Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA

✍ Ron Rodriguez 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 35 KB